Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in crohn's disease

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 7, 2015, Pages 1293-1301.e5

  Osterman, Mark T ^a   Haynes, Kevin ^b   Delzell, Elizabeth ^c   Zhang, Jie ^c   Bewtra, Meenakshi ^a,b   Brensinger, Colleen M ^b   Chen, Lang ^d   Xie, Fenglong ^d   Curtis, Jeffrey R ^c,d   Lewis, James D ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d University of Alabama at Birmingham   (United States)

Author keywords

Adalimumab; Hospitalization; Infection; Infliximab; Surgery; Thiopurines

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ADALIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; YOUNG ADULT; ABDOMINAL SURGERY; AGED; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; HOSPITALIZATION; OPPORTUNISTIC INFECTIONS; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HOSPITALIZATION; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84931371979     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2015.02.017     Document Type: Article

References (30)

1. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. NEngl J Med 2010, 362:1383-1395.
2. Van Assche G., Magdelaine-Beuzelin M., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
3. Lichtenstein G.R., Diamond R.H., Wagner C.L., et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009, 30:210-226.
4. Sokol H., Seksik P., Carrat F., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2011, 59:1363-1368.
5. Reenaers C., Louis E., Belaiche J., et al. Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?. Aliment Pharmacol Ther 2012, 36:1040-1048.
6. Vermeire S., Noman M., Van Assche, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
7. Bortlik M., Duricova D., Malickova K., et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. JCrohns Colitis 2013, 7:736-743.
8. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. NEngl J Med 2003, 348:601-608.
9. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. NEngl J Med 2004, 350:876-885.
10. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
11. Maser E.A., Villela R., Silverberg M.S., et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
12. Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-1125.
13. Peyrin-Biroulet L., Khosrotehrani K., Carrat F., et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011, 141:1621-1628.
14. Osterman M.T., Sandborn W.J., Colombel J.-F., et al. Increased risk of malignancy with adalimumab combination therapy, compared to monotherapy, in Crohn's disease. Gastroenterology 2014, 146:941-949.
15. Gupta G., Lautenbach E., Lewis J.D. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:1483-1490.
16. Osterman M.T., Lichtenstein G.R. Current and future anti-TNF therapy for inflammatory bowel disease. Curr Treat Options Gastroenterol 2007, 10:195-207.
17. Toruner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
18. Osterman M.T., Haynes K., Delzell E., et al. Comparative effectiveness of infliximab and adalimumab for Crohn's disease. Clin Gastroenterol Hepatol 2014, 12:811-817.
19. Grijalva C.G., Chen L., Delzell E., et al. Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune disease. JAMA 2011, 306:2331-2339.
20. Beukelman T., Xie F., Baddley J.W., et al. Incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. Arthritis Rheum 2013, 65:1384-1389.
21. Baddley J.W., Winthrop K.L., Chen L., et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety assessment of Biologic thERapy (SABER) study. Ann Rheum Dis 2014, 73:1942-1948.
22. Schneeweiss S., Wang P.S., Avorn J., et al. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res 2003, 38:1103-1120.
23. Awni W.M., Eckert D., Sharma S., et al. Pharmacokinetics of adalimumab in adult patients with moderately to severely active ulcerative colitis. Gastroenterology 2013, 144(Suppl 1):S-229.
24. Hanauer S.B., Feagan G., Lichtenstein G.R., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
25. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol 2011, 106:674-684.
26. Linton M.S., Kroeker K., Fedorak D., et al. Prevalence of Epstein-Barr virus in a population of patients with inflammatory bowel disease: a prospective cohort study. Aliment Pharmacol Ther 2013, 38:1248-1254.
27. Camus M., Seksik P., Bourrier A., et al. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin Gastroenterol Hepatol 2013, 11:389-394.
28. Pasternak B., Svanstrom H., Schmiegelow K., et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013, 177:1296-1305.
29. Askling J., Fahrbach K., Nordstrom B., et al. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011, 20:119-130.
30. Melmed G.Y. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis 2009, 15:1410-1416.